08:00 – 10:00 |
Session 7         Clinical Trials in Sepsis – Lessons from the Past and Ongoing Trials |
08:00 – 08:45 |
Keynote 3 – Introduced by Simon Finfer |
|
Pragmatic trials: a bold new paradigm for sepsis research |
|
Stephen MacMahon, Sydney, Australia |
08:45 – 09:15 |
Round table – Why do so many sepsis trials fail? |
09:15 – 10:00 |
Session 8 Update on Ongoing Clinical Trials          Part I |
|
Chairs: Mervyn Singer and Derek Angus |
09:15 – 09:30 |
Talactoferrin Alfa Reduces Mortality in Severe Sepsis ? results of a phase II trial. -
|
|
Steve Opal, Pawtucket, USA |
09:30 – 09:45 |
PROWESS SHOCK: Activated protein C in septic shock |
|
Marco Ranieri, Turin, Italy |
09:45 – 10:00 |
Activated protein C and Corticosteroids |
|
Djillali Annane, Paris, France |
10:00 – 10:30 |
BREAK |
10:30 – 12:30 |
Session 8         Update on Ongoing Clinical Trials   Part II |
|
Chairs: Simon Finfer and John Marshall |
10:30 – 10:45 |
ACCESS – Eritoran, a TLR4 antagonist in severe sepsis |
|
Steve Opal, Pawtucket, USA |
10:45 – 11:00 |
Early Goal Directed Therapy: ProCESS, ARISE and ProMISE |
|
Derek Angus, Pittsburgh, USA |
11:00 – 11:15 |
Fluid resuscitation in Australia and New Zealand- The CHEST trial |
|
John Myburgh, Sydney, Australia |
11:15 – 11:30 |
LPS removal |
|
John Marshall, Torotno, Canada |
11:30 – 11:45 |
European revival of albumin in sepsis: EARSS and ALBIOS |
|
Jean-Paul Mira, Paris, France |
11:45 – 12:00 |
Fluid resuscitation in Africa |
|
Kath Maitland, Kalifi, Kenya |
12:00 – 12:15 |
InFACT – did we learn anything from H1N1? |
|
John Marshall, Toronto, Canada |
12:15 – 12:30 |
Chairs’ wrap-up and closing comments |